The NIH translational research center might trade public risk for private reward

Nature Medicine

Volumn 17, Issue 10, 2011, Pages 1176-

  Avorn, Jerry ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IMATINIB; NEW DRUG; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ALZHEIMER DISEASE; BASIC RESEARCH; BUDGET; CANCER CHEMOTHERAPY; DRUG INDUSTRY; DRUG RESEARCH; ECONOMIC ASPECT; MEDICAL RESEARCH; NEOPLASM; NOTE; PRIORITY JOURNAL; UNITED STATES;

COMMERCE; DRUG DISCOVERY; NATIONAL INSTITUTES OF HEALTH (U.S.); RISK; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 80053984580     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1011-1176     Document Type: Note

References (3)

1. Collins F. Nat. Rev. Drug Discov. 10, 14 (2011).
2. Stevens A.J., et al. N. Engl. J. Med. 364, 535-541 (2011).
3. Collins, F. 27 Apr 2011. The NIH National Center for Advancing Translational Sciences: How Will It Work? 〈https://www.dtmi.duke.edu/ website-administration/files/Collins%20 NCATS%20slides.pdf〉 (2011; last accessed 16 Sept 2011).